Importance: Findings from unbiased genetic studies have consistently implicated synaptic protein networks in schizophrenia, but the molecular pathologic features within these networks and their contribution to the synaptic and circuit deficits thought to underlie disease symptoms remain unknown. Objective: To determine whether protein levels are altered within synapses from the primary auditory cortex (A1) of individuals with schizophrenia and, if so, whether these differences are restricted to the synapse or occur throughout the gray matter. Design, Setting, and Participants: This paired case-control study included tissue samples from individuals with schizophrenia obtained from the Allegheny County Office of the Medical Examiner. An independent panel of health care professionals made consensus DSM-IV diagnoses. Each tissue sample from an individual with schizophrenia was matched by sex, age, and postmortem interval with 1 sample from an unaffected control individual. Targeted mass spectrometry was used to measure protein levels in A1 gray matter homogenate and synaptosome preparations. All experimenters were blinded to diagnosis. Mass spectrometry data were collected from September 26 through November 4, 2016, and analyzed from November 3, 2016, to July 15, 2019. Main Outcomes and Measures: Primary measures were homogenate and synaptosome protein levels and their coregulation network features. Hypotheses generated before data collection were (1) that levels of canonical postsynaptic proteins in A1 synaptosome preparations would differ between individuals with schizophrenia and controls and (2) that these differences would not be explained by changes in total A1 homogenate protein levels. Results: Synaptosome and homogenate protein levels were investigated in 48 individuals with a schizophrenia diagnosis and 48 controls (mean age in both groups, 48 years [range, 17-83 years]); each group included 35 males (73%) and 13 females (27%). Robust alterations (statistical cutoff set at an adjusted Limma P < .05) were observed in synaptosome levels of canonical mitochondrial and postsynaptic proteins that were highly coregulated and not readily explained by postmortem interval, antipsychotic drug treatment, synaptosome yield, or underlying alterations in homogenate protein levels. Conclusions and Relevance: These findings suggest a robust and highly coordinated rearrangement of the synaptic proteome. In line with unbiased genetic findings, alterations in synaptic levels of postsynaptic proteins were identified, providing a road map to identify the specific cells and circuits that are impaired in individuals with schizophrenia A1.
Importance: Findings from unbiased genetic studies have consistently implicated synaptic protein networks in schizophrenia, but the molecular pathologic features within these networks and their contribution to the synaptic and circuit deficits thought to underlie disease symptoms remain unknown. Objective: To determine whether protein levels are altered within synapses from the primary auditory cortex (A1) of individuals with schizophrenia and, if so, whether these differences are restricted to the synapse or occur throughout the gray matter. Design, Setting, and Participants: This paired case-control study included tissue samples from individuals with schizophrenia obtained from the Allegheny County Office of the Medical Examiner. An independent panel of health care professionals made consensus DSM-IV diagnoses. Each tissue sample from an individual with schizophrenia was matched by sex, age, and postmortem interval with 1 sample from an unaffected control individual. Targeted mass spectrometry was used to measure protein levels in A1 gray matter homogenate and synaptosome preparations. All experimenters were blinded to diagnosis. Mass spectrometry data were collected from September 26 through November 4, 2016, and analyzed from November 3, 2016, to July 15, 2019. Main Outcomes and Measures: Primary measures were homogenate and synaptosome protein levels and their coregulation network features. Hypotheses generated before data collection were (1) that levels of canonical postsynaptic proteins in A1 synaptosome preparations would differ between individuals with schizophrenia and controls and (2) that these differences would not be explained by changes in total A1 homogenate protein levels. Results: Synaptosome and homogenate protein levels were investigated in 48 individuals with a schizophrenia diagnosis and 48 controls (mean age in both groups, 48 years [range, 17-83 years]); each group included 35 males (73%) and 13 females (27%). Robust alterations (statistical cutoff set at an adjusted Limma P < .05) were observed in synaptosome levels of canonical mitochondrial and postsynaptic proteins that were highly coregulated and not readily explained by postmortem interval, antipsychotic drug treatment, synaptosome yield, or underlying alterations in homogenate protein levels. Conclusions and Relevance: These findings suggest a robust and highly coordinated rearrangement of the synaptic proteome. In line with unbiased genetic findings, alterations in synaptic levels of postsynaptic proteins were identified, providing a road map to identify the specific cells and circuits that are impaired in individuals with schizophrenia A1.
Authors: Michael J Gandal; Pan Zhang; Evi Hadjimichael; Rebecca L Walker; Chao Chen; Shuang Liu; Hyejung Won; Harm van Bakel; Merina Varghese; Yongjun Wang; Annie W Shieh; Jillian Haney; Sepideh Parhami; Judson Belmont; Minsoo Kim; Patricia Moran Losada; Zenab Khan; Justyna Mleczko; Yan Xia; Rujia Dai; Daifeng Wang; Yucheng T Yang; Min Xu; Kenneth Fish; Patrick R Hof; Jonathan Warrell; Dominic Fitzgerald; Kevin White; Andrew E Jaffe; Mette A Peters; Mark Gerstein; Chunyu Liu; Lilia M Iakoucheva; Dalila Pinto; Daniel H Geschwind Journal: Science Date: 2018-12-14 Impact factor: 47.728
Authors: L J Garey; W Y Ong; T S Patel; M Kanani; A Davis; A M Mortimer; T R Barnes; S R Hirsch Journal: J Neurol Neurosurg Psychiatry Date: 1998-10 Impact factor: 10.154
Authors: María D Rubio; Krista Wood; Vahram Haroutunian; James H Meador-Woodruff Journal: Neuropsychopharmacology Date: 2013-04-09 Impact factor: 7.853
Authors: Anthony J Deo; Isaac M Goldszer; Siyu Li; James V DiBitetto; Ruth Henteleff; Allan Sampson; David A Lewis; Peter Penzes; Robert A Sweet Journal: PLoS One Date: 2013-04-22 Impact factor: 3.240
Authors: Tineke Grent-'t-Jong; Ruchika Gajwani; Joachim Gross; Andrew I Gumley; Stephen M Lawrie; Matthias Schwannauer; Frauke Schultze-Lutter; Stephen R Williams; Peter J Uhlhaas Journal: Front Psychiatry Date: 2022-03-29 Impact factor: 4.157
Authors: M J Grubisha; X Sun; M L MacDonald; M Garver; Z Sun; K A Paris; D S Patel; R A DeGiosio; D A Lewis; N A Yates; C Camacho; G E Homanics; Y Ding; R A Sweet Journal: Mol Psychiatry Date: 2021-02-01 Impact factor: 15.992